Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection
Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection
复制标题
DOI：
10.1023/b:joci.0000019778.96564.26
复制
发表时间：
2004-03-01
影响因子：
9.1
通讯作者：
Levy, JA
中科院分区：
文献类型：
--
作者：
Martinez-Mariño, B;Ashlock, BM;Levy, JA
在人类免疫缺陷病毒（HIV）感染期间的早期治疗干预是旨在保持和/或增强正在形成的抗HIV免疫应答的策略。我们报告了高效抗逆转录病毒治疗（HAART）联合间断皮下注射白细胞介素2（IL-2）对原发性HIV-1感染受试者的CD 8（+）细胞非细胞毒性抗HIV应答（CNAR）以及病毒载量和CD 4（+）细胞/CD 8（+）细胞数量的影响。24例患者接受HAART，24例接受HAART + IL-2联合治疗，12例选择不治疗。与单独HAART相比，IL-2治疗导致研究第48周CD 4（+）细胞数量显著增加。未观察到对病毒载量或CD 8（+）细胞群的影响。第一个周期的IL-2增强CNAR;以后的周期没有显示出实质性的影响。这项研究表明，HAART联合IL-2可以在治疗早期HIV感染中提供免疫学益处。
Early treatment intervention during human immunodeficiency virus (HIV) infection is a strategy aimed to preserve and/or enhance the developing anti-HIV immune responses. We report the effect of highly active antiretroviral therapy ( HAART) combined with intermittent subcutaneous doses of Interleukin 2 (IL-2) on CD8(+) cell noncytotoxic anti-HIV responses (CNAR), as well as on viral loads and CD4(+) cell/CD8(+) cell numbers in subjects with primary HIV-1 infection. Twenty-four patients received HAART, 24 received a combination of HAART plus IL-2, and 12 elected no-therapy. In comparison to HAART alone, IL-2 treatment led to significant increases in CD4(+) cell numbers through week 48 of the study. No effect was observed on viral loads or the CD8(+) cell population. The first cycle of IL-2 enhanced CNAR; later cycles showed no substantial effect. This study suggests that HAART combined with IL-2 could provide an immunologic benefit in the treatment of early HIV infection.